This TriNetX study compared people starting semaglutide with people undergoing sleeve gastrectomy or gastric bypass [1]. The cost comparison for GLP-1 treatment and bariatric surgery addresses a separate decision. The study measured a combined outcome of coronary events, cerebrovascular events, heart failure and cardiac arrest.
What were the event rates?
Researchers matched 11,466 pairs without type 2 diabetes and 7,327 pairs with it. During follow-up of up to five years, the recorded rates without diabetes were 4.4% after surgery and 6.6% with semaglutide. The hazard ratio was 0.402 (95% CI 0.356–0.454)[1]. With diabetes, the recorded rates were 9.0% and 14.6% respectively. The hazard ratio was 0.421 (95% CI 0.381–0.465) [1].
Can matching explain the difference?
Matching balanced measured characteristics. Surgical eligibility and other unmeasured differences could still affect the comparison. Research on how long people stay on GLP-1 treatment also helps explain why starting treatment is different from taking it throughout follow-up. The authors varied refill requirements in sensitivity analyses, and the direction of the results stayed consistent [1].